Previous 10 | Next 10 |
NEW YORK and CLEVELAND, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and sell shares of its common stock and warrants to purchase common stock in an underwritten public...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com News moving stocks today include earnings rep...
NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second annual Venture Into Cures , a virtual event supporting EB Research Partnership's mission t...
NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the company’s ABO-102 pivotal Transpher A study in Sanfilippo syndrome type A (MPS IIIA) will ...
NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Executive Officer of Abeona, will participate virtually in a fireside chat at the Jefferies...
Abeona Therapeutics (NASDAQ:ABEO): Q3 GAAP EPS of -$0.07 beats by $0.09. Cash, cash equivalents and short-term investments of $67M. Press Release For further details see: Abeona Therapeutics EPS beats by $0.09
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! We’re getting right into the thick of it this week with a look at the biggest pre-market stock movers for Monday! Source: Eric Urquhart/Shutterstock.com Moving stocks today are earnings ...
NEW YORK and CLEVELAND, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., Chief Executive Officer of Abeona, is scheduled to present at the Jefferies Gene Therapy/...
NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021. The presentations...
NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice President, Head of Quality. Mr. Voss, who has been advising the Company as a consultant,...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...